Skip to main content
Top
Gepubliceerd in:

17-05-2017 | S.I. : Autism Inpatient Collection - Studying the Severely Affected

Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder

Auteurs: Logan K. Wink, Ernest V. Pedapati, Ryan Adams, Craig A. Erickson, Kahsi A. Pedersen, Eric M. Morrow, Desmond Kaplan, Matthew Siegel, for the Autism and Developmental Disorders Inpatient Research Collaborative (ADDIRC)

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 11/2018

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Nearly 11% of youth with Autism Spectrum Disorder (ASD) undergo psychiatric hospitalization, and 65% are treated with psychotropic medication. Here we characterize psychotropic medication usage in subjects enrolled in the Autism Inpatient Collection. Participant psychotropic medication usage rates topped 90% at admission and discharge, though there was a decline at 2-month follow-up. Antipsychotics, ADHD medications, and sleep aids were the most commonly reported classes of medications. The impact of age, gender, and non-verbal IQ on medication usage rates was minimal, though age and IQ may play a role in prescribing practices. Future work is indicated to explore medication usage trends, the impact of clinical factors on medication use rates, and the safety of psychotropic medications in youth with ASD.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
go back to reference Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491. Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491.
go back to reference Christensen, D. L. (2016). Prevalence and characteristics of autism spectrum disorder among children aged 8 years- autism developmental disabilities monitoring network. Surveillance Summaries 65. Christensen, D. L. (2016). Prevalence and characteristics of autism spectrum disorder among children aged 8 years- autism developmental disabilities monitoring network. Surveillance Summaries 65.
go back to reference Erickson, C. A., Posey, D. J., Stigler, K. A., & McDougle, C. J. (2007). Pharmacologic treatment of autism and related disorders. Pediatric Annals, 36, 575–585.CrossRefPubMed Erickson, C. A., Posey, D. J., Stigler, K. A., & McDougle, C. J. (2007). Pharmacologic treatment of autism and related disorders. Pediatric Annals, 36, 575–585.CrossRefPubMed
go back to reference Lord, C., Rutter, M., DiLavore, P., Risis, S., Gotham, K., & Bishop, S. (2012). Autism diagnostic observation schedule, second edition (ADOS-2). Torrance: Western Psychological Services. Lord, C., Rutter, M., DiLavore, P., Risis, S., Gotham, K., & Bishop, S. (2012). Autism diagnostic observation schedule, second edition (ADOS-2). Torrance: Western Psychological Services.
go back to reference Marcus, R. N., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 1110–1119. doi:10.1097/CHI.0b013e3181b76658.CrossRefPubMed Marcus, R. N., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 1110–1119. doi:10.​1097/​CHI.​0b013e3181b76658​.CrossRefPubMed
go back to reference McCracken, J. T., et al. (2002). Risperidone in children with autism and serious behavioral problems. The New England Journal of Medicine, 347, 314–321.CrossRefPubMed McCracken, J. T., et al. (2002). Risperidone in children with autism and serious behavioral problems. The New England Journal of Medicine, 347, 314–321.CrossRefPubMed
go back to reference Molloy, C. A., & Manning-Courtney, P. (2003). Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders. Autism, 7, 165–171.CrossRefPubMed Molloy, C. A., & Manning-Courtney, P. (2003). Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders. Autism, 7, 165–171.CrossRefPubMed
go back to reference Park, S. Y., et al. (2016). Antipsychotic use trends in youth with autism spectrum disorder and/or intellectual disability: A meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 55(456–468), e4. doi:10.1016/j.jaac.2016.03.012.CrossRef Park, S. Y., et al. (2016). Antipsychotic use trends in youth with autism spectrum disorder and/or intellectual disability: A meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 55(456–468), e4. doi:10.​1016/​j.​jaac.​2016.​03.​012.CrossRef
go back to reference Research Units on Pediatric Psychopharmacology Autism Network (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62, 1266–1274 doi:10.1001/archpsyc.62.11.1266.CrossRef Research Units on Pediatric Psychopharmacology Autism Network (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62, 1266–1274 doi:10.​1001/​archpsyc.​62.​11.​1266.CrossRef
go back to reference Roid, G. H., Miller, L. J., Pomplun, M., Koch, C. (2013). Leiter international performance scale, 3rd Edition. Wood Dail, IL: Stoelting. Roid, G. H., Miller, L. J., Pomplun, M., Koch, C. (2013). Leiter international performance scale, 3rd Edition. Wood Dail, IL: Stoelting.
go back to reference Rutter, M., Bailey, A., Lord, C. (2003). Social communication questionnaire. Torrance: Western Psychological Services. Rutter, M., Bailey, A., Lord, C. (2003). Social communication questionnaire. Torrance: Western Psychological Services.
go back to reference Schubart, J. R., Camacho, F., & Leslie, D. (2014). Psychotropic medication trends among chidren and adolescents with autism psectrum disorder in the Medicaid program. Autism, 18, 631–637.CrossRefPubMed Schubart, J. R., Camacho, F., & Leslie, D. (2014). Psychotropic medication trends among chidren and adolescents with autism psectrum disorder in the Medicaid program. Autism, 18, 631–637.CrossRefPubMed
go back to reference Sparrow, S., Cicchetti, D., Balla, D.A. (2008). Vineland adaptive behaviors scales, 2nd Edition. Livonia: Pearson. Sparrow, S., Cicchetti, D., Balla, D.A. (2008). Vineland adaptive behaviors scales, 2nd Edition. Livonia: Pearson.
go back to reference Wink, L. K., Erickson, C. A., & McDougle, C. J. (2010). Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Current Treatment Options in Neurology, 12, 529–538. doi:10.1007/s11940-010-0091-8.CrossRefPubMed Wink, L. K., Erickson, C. A., & McDougle, C. J. (2010). Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Current Treatment Options in Neurology, 12, 529–538. doi:10.​1007/​s11940-010-0091-8.CrossRefPubMed
Metagegevens
Titel
Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder
Auteurs
Logan K. Wink
Ernest V. Pedapati
Ryan Adams
Craig A. Erickson
Kahsi A. Pedersen
Eric M. Morrow
Desmond Kaplan
Matthew Siegel
for the Autism and Developmental Disorders Inpatient Research Collaborative (ADDIRC)
Publicatiedatum
17-05-2017
Uitgeverij
Springer US
Gepubliceerd in
Journal of Autism and Developmental Disorders / Uitgave 11/2018
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI
https://doi.org/10.1007/s10803-017-3153-x